News - Teva Pharmaceutical Industries, Rare diseases

Filter

Popular Filters

FDA approves Raptor's Procysbi for rare genetic condition; and Plan B One-Step

01-05-2013

US drugmaker Raptor Pharmaceuticals (Nasdaq: RPTP) saw its share price rise 7.5% to $7.06 in mid-afternoon…

North AmericaPharmaceuticalPlan B One-StepProcysbiRaptor PharmaceuticalsRare diseasesRegulationReproductiveTeva Pharmaceutical IndustriesWomen's Health

Merck returns safinamide rights to Newron; ImmuPharma regains Lupuzor from Cephalon

24-10-2011

As part of the ongoing review and re-prioritization of its R&D pipeline, biotech firm Merck Serono, a…

BiotechnologyCephalonLicensingLupuzorMerck KGaAMerck SeronoNeurologicalNewron PharmaPharmaceuticalRare diseasessafinamideTeva Pharmaceutical Industries

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top